The Global Neurological Biomarkers Market is Predict to reach $12.9 Billion by 2028, at a CAGR of 14.2%

Published Date: 24-Nov-2022

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Neurological Biomarkers Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Neurological Biomarkers Market size is expected to reach $4.0 billion by 2028, rising

According to a new report, published by KBV research, The Global Neurological Biomarkers Market size is expected to reach $12.9 billion by 2028, rising at a market growth of 14.2% CAGR during the forecast period.

The Proteomic market acquired maximum revenue share in the Global Neurological Biomarkers Market by Type in 2021; thereby, achieving a market value of $4.0 Billion by 2028. Due to the widespread use of proteomic biomarkers in neurological disorder research. Since denatured proteins or protein aggregates cause neurodegenerative disorders, proteomics is very helpful in understanding how these disorders arise.

The Parkinson’s Disease market is exhibiting a CAGR of 14.3% during (2022 - 2028). The second most prevalent neurodegenerative ailment is Parkinson's disease. Parkinson's disease patients have a gradual decline in motor function over time as a result of the death of dopamine-producing brain cells.

The North America market dominated the Global Neurological Biomarkers Market by Region in 2021; thereby, achieving a market value of $4.8 Billion by 2028. The Europe market is experiencing a CAGR of 13.7% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 15% during (2022 - 2028).

Full Report: https://www.kbvresearch.com/neurological-biomarkers-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of F. HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group, PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMérieux S.A. and Myriad Genetics, Inc.

Global Neurological Biomarkers Market Segmentation

By Type

  • Proteomic
  • Genomic
  • Metabolomic
  • Others

By Application

  • Alzheimer's Disease
  • Parkinson’s Disease
  • Multiple Sclerosis

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Australia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • F.HOFFMANN-LA ROCHE LTD.
  • Bio-Rad Laboratories, Inc.
  • Merck Group
  • PERKINELMER INC.
  • Shimadzu corporation
  • Thermo Fisher Scientific, Inc.
  • Quanterix Corporation
  • Neuro-Bio Ltd.
  • BioMérieux S.A.
  • Myriad Genetics, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

North America Neurological Biomarkers Market Future Scope & Opportunities 2022-2028

Europe Neurological Biomarkers Market Size & Growth Forecast 2022-2028

Asia Pacific Neurological Biomarkers Market Size, Share & Industry Outlook to 2028

LAMEA Neurological Biomarkers Market Growth, Trends & Forecasts 2022-2028

Request a Free Sample Copy


Why Choose Us

  • 24/7 Research support
    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Information security
    Your personal and confidential information is safe and secure.